Short answer · Medically reviewed summary · Last updated: 2026-05-08
TL;DR: The standard treatment for Wilms tumor typically involves a multidisciplinary approach combining surgical resection (nephrectomy) with risk-stratified chemotherapy and, occasionally, radiation therapy. Treatment plans for Wilms tumor are highly personalized based on the tumor's histology (favorable vs.
TL;DR: The standard treatment for Wilms tumor typically involves a multidisciplinary approach combining surgical resection (nephrectomy) with risk-stratified chemotherapy and, occasionally, radiation therapy. Treatment plans for Wilms tumor are highly personalized based on the tumor's histology (favorable vs. unfavorable), clinical stage, and the child's age at diagnosis.
Treatment for Wilms tumor is determined by the Children’s Oncology Group (COG) protocols in North America or the SIOP protocols internationally. Surgery is almost always the first step to remove the affected kidney (nephrectomy) and evaluate lymph nodes. Following surgery, chemotherapy is administered to destroy any remaining cancer cells. Common medications include vincristine (Oncovin), dactinomycin (Cosmegen), and doxorubicin (Adriamycin). Radiation therapy is specifically reserved for cases where the tumor is stage III or IV, or if there is unfavorable histology.
Because Wilms tumor requires complex, coordinated care, patients should be managed by a multidisciplinary team. Key members include:
The prognosis for Wilms tumor is generally excellent, with overall survival rates exceeding 90% for favorable histology tumors. Effectiveness varies based on the "stage" (how far the tumor has spread) and "histology" (how the cells look under a microscope). Patients with bilateral Wilms tumor (affecting both kidneys) require more complex, organ-sparing surgical approaches to preserve as much healthy kidney tissue as possible.
Current clinical research for Wilms tumor is focused on reducing the long-term side effects of chemotherapy while maintaining high cure rates. Researchers are investigating molecular markers to identify patients who may safely receive less intensive treatment, as well as targeted therapies for rare, relapsed, or resistant forms of the disease.
Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment; always consult your oncology team regarding specific clinical decisions.